About Us » View of Opinion Leaders
Prof. Jeff S. Borer
Professor Borer is the Chief of the Cardiovascular Pathophysiology Division, Weill Medical College at Cornell University, New York. Professor Borer is an opinion leader in the fields of cardiovascular disorders, such as congestive heart failure, coronary artery disease, ischemic heart disease and valvular heart disease. Professor Borer served in the past as Chairman of the FDA Cardiovascular and Renal Drugs Advisory Committee.
MTR 105 has the potential (…) to be particularly useful in a variety of settings where management of hypotension is necessary. An area particularly familiar to me in which it might be quite useful is the early post-cardiopulmonary bypass period after cardiac surgery; dramatic fluid shifts occur immediately after patients are weaned from cardio-pulmonary bypass, resulting in profound hypotension that needs to be reversed very quickly. (…)
(…) Other applications also may be important, for example, in patients who undergo fluid shifts and consequent fall in blood pressure in other settings, such as non cardiac surgery with epidural anesthesia, or hemodialysis. And if the IV preparation works as we believe it does from our preliminary data, then development of an oral formulation opens the potential for application in several other critically important states where low blood pressure is a problem, including chronic asthenia, chronic fatigue syndrome, idiopathic hypotension. (…)
(…) Therefore, I think this is potentially a very useful product and I am very excited about the possibility of being involved with its development.
Ze’ev Katzir, MD
Senior adult nephrologist and principal senior pediatric nephrologist at Wolfson Medical Center.
Clinical Experience with Eight Patients who Received MTR105 in the Beginning of Hemodialysis Session:
Eight patients from the Nephrology Dialysis and Kidney Transplantation Ward of the Moldova National Hospital in Kishinev (Chisinau) received bolus intravenous injection of 0.6 mg/kg MTR-105 in the beginning of their regular hemodialysis sessions as a part of hemodialysis pharmacokinetic study. All these patients were known to develop intradyalitic hypotension.
Following administration of MTR-105, the patients were hemodinamically stable during the first two hours of therapy.
They did not demonstrated adverse reactions and/or hypertension along the rest of the hemodialysis session and during four hours post dialysis.
The treatment, clinical observation and monitoring were performed under my personal supervision.
Amnon Mosek, M.D.
Deputy Head of Neuorological Dept at Ichilov Medical Centre, Tel aviv, and Co-Principal Investigator of the Migraine study in Moldova.
Preliminary open label studies on MTR106 showed that this compound is highly effective in alleviating migraine headache. The time to achieve headache relief was shorter than that reported for known anti-migraine drugs such as the serotonin agonists with no significant side effects. The noted decrease during the study in the heart rate and an increase in the blood pressure were not accompanied by clinical symptoms.
In my opinion, MTR106 is potentially a very useful product in the treatment of migraine.
Prof. Arie Schachner
Head of the Cardiothoracic Surgery Department, Wolfson Medical Center, Tel Aviv.
I personally witnessed at least 10 patients who have been administered with MTR105 during hypotensive episodes after cardiac surgery. The low blood pressure was immediately normalized, and more importantly no overshoot of blood pressure occurred, as is often encountered with sympathomimetic drugs. As a surgeon I always verify blood supply to the periphery, and with MTR105 the patient’s extremities were warm and with normal color. I think that MTR105 has a great potential in the treatment of Low Blood pressure (LBP).
